Verona Pharma Announces March 2025 Investor Conference Participation

GlobeNewswire

02-18

NEW_VeronaCorp_Logo_Inline_With_RGB - for notfied.jpg

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:

TD Cowen 45^th Annual Health Care Conference
Date: Monday, March 3, 2025
Time: 11:10 a.m. ET / 4:10 p.m. GMT
Location: Boston, MA

Leerink Partners 2025 Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 8:40 a.m. ET / 1:40 p.m. GMT
Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners US Investor Enquiries	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com
Wendy Ryan

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512587741"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512587741\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512587741?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-18 19:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2512587741","market":"us","top_or_hot":-1,"title":"Verona Pharma Announces March 2025 Investor Conference Participation","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/bovPyM7JTsbcYOObRMb6Eg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/1d6ea1f718912f68e97a5c342dcdc6af\" title=\"NEW_VeronaCorp_Logo_Inline_With_RGB - for notfied.jpg\" vspace=\"5\"/>\n<p>LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:</p>\n<p><strong>TD Cowen 45</strong><sup><strong>th</strong></sup><strong> Annual Health Care Conference<br/></strong>Date: Monday, March 3, 2025<br/>Time: 11:10 a.m. ET / 4:10 p.m. GMT<br/>Location: Boston, MA<br/><br/></p>\n<p><strong>Leerink Partners 2025 Global Healthcare Conference<br/></strong>Date: Monday, March 10, 2025<br/>Time: 8:40 a.m. ET / 1:40 p.m. GMT<br/>Location: Miami, FL<br/><br/></p>\n<p>A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.</p>\n<p>For further information please contact:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Verona Pharma plc</strong></td>\n<td>Tel: +1-844-341-9901</td>\n</tr>\n<tr>\n<td>Victoria Stewart, Senior Director of Investor Relations and Communications</td>\n<td>IR@veronapharma.com</td>\n</tr>\n<tr>\n<td><strong>Argot Partners</strong><br/>US Investor Enquiries<br/></td>\n<td>Tel: +1-212-600-1902<br/>verona@argotpartners.com<br/></td>\n</tr>\n<tr>\n<td><strong>Ten Bridge Communications</strong><br/>International / US Media Enquiries<br/></td>\n<td>Tel: +1-781-316-4424<br/>tbcverona@tenbridgecommunications.com <br/></td>\n</tr>\n<tr>\n<td>Wendy Ryan</td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p><strong><br/>About Verona Pharma<br/></strong></p>\n<p>Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.</p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verona Pharma Announces March 2025 Investor Conference Participation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerona Pharma Announces March 2025 Investor Conference Participation\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-02-18 19:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/bovPyM7JTsbcYOObRMb6Eg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/1d6ea1f718912f68e97a5c342dcdc6af\" title=\"NEW_VeronaCorp_Logo_Inline_With_RGB - for notfied.jpg\" vspace=\"5\"/>\n<p>LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:</p>\n<p><strong>TD Cowen 45</strong><sup><strong>th</strong></sup><strong> Annual Health Care Conference<br/></strong>Date: Monday, March 3, 2025<br/>Time: 11:10 a.m. ET / 4:10 p.m. GMT<br/>Location: Boston, MA<br/><br/></p>\n<p><strong>Leerink Partners 2025 Global Healthcare Conference<br/></strong>Date: Monday, March 10, 2025<br/>Time: 8:40 a.m. ET / 1:40 p.m. GMT<br/>Location: Miami, FL<br/><br/></p>\n<p>A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.</p>\n<p>For further information please contact:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Verona Pharma plc</strong></td>\n<td>Tel: +1-844-341-9901</td>\n</tr>\n<tr>\n<td>Victoria Stewart, Senior Director of Investor Relations and Communications</td>\n<td>IR@veronapharma.com</td>\n</tr>\n<tr>\n<td><strong>Argot Partners</strong><br/>US Investor Enquiries<br/></td>\n<td>Tel: +1-212-600-1902<br/>verona@argotpartners.com<br/></td>\n</tr>\n<tr>\n<td><strong>Ten Bridge Communications</strong><br/>International / US Media Enquiries<br/></td>\n<td>Tel: +1-781-316-4424<br/>tbcverona@tenbridgecommunications.com <br/></td>\n</tr>\n<tr>\n<td>Wendy Ryan</td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p><strong><br/>About Verona Pharma<br/></strong></p>\n<p>Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.</p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/verona-pharma-announces-march-2025-110000866.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://finance.yahoo.com/news/verona-pharma-announces-march-2025-110000866.html","article_id":"2512587741","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512587741","pubTimestamp":1739876400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"TD Cowen 45th Annual Health Care ConferenceDate: Monday, March 3, 2025Time: 11:10 a.m. ET / 4:10 p.m. GMTLocation: Boston, MA. Leerink Partners 2025 Global Healthcare ConferenceDate: Monday, March 10, 2025Time: 8:40 a.m. ET / 1:40 p.m. GMTLocation: Miami, FL. Victoria Stewart, Senior Director of Investor Relations and Communications","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","VRNA":"维罗纳制药"},"translate_title":"Verona Pharma宣布参加2025年3月投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":0.9},"content_text":"LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:\nTD Cowen 45th Annual Health Care ConferenceDate: Monday, March 3, 2025Time: 11:10 a.m. ET / 4:10 p.m. GMTLocation: Boston, MA\nLeerink Partners 2025 Global Healthcare ConferenceDate: Monday, March 10, 2025Time: 8:40 a.m. ET / 1:40 p.m. GMTLocation: Miami, FL\nA webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.\nFor further information please contact:\n\n\n\nVerona Pharma plc\nTel: +1-844-341-9901\n\n\nVictoria Stewart, Senior Director of Investor Relations and Communications\nIR@veronapharma.com\n\n\nArgot PartnersUS Investor Enquiries\nTel: +1-212-600-1902verona@argotpartners.com\n\n\nTen Bridge CommunicationsInternational / US Media Enquiries\nTel: +1-781-316-4424tbcverona@tenbridgecommunications.com \n\n\nWendy Ryan\n \n\n\n\nAbout Verona Pharma\nVerona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}